"Research use only" is a seller's statement that a product is meant for laboratory experiments, not for people. It is not an approval, a licence or a quality standard. Regulators in the United States, Canada, Australia and the United Kingdom have said that when such products are in fact marketed for human use, the label does not make the sale legal, and regulators have not assessed these products for safety, quality or effectiveness.1,
What the label says
The wording varies. FDA warning letters quote labels such as "for laboratory, research, and analytical use", "not intended for human or veterinary use", "Research Use Only" and "not intended for human consumption, medical use, or veterinary use". Health Canada reports products marked "For Research Use Only" and "Not for Human Consumption". Pharmacists at the University of Connecticut have described vials of semaglutide and tirzepatide sold to consumers without a prescription under "research purposes only" or "not for human consumption" labels.1,
The label matters less than it seems. In US law, whether a product is a drug depends on its "intended use", and an FDA regulation says intended use is judged by objective intent. That intent can be shown by labelling claims, advertising, statements by the seller and the circumstances in which a product is sold, not only by the wording on the vial.4,
Why regulators say the label does not make sales legal
United States. In warning letters dated March 31 and August 24, 2026, the FDA told two online sellers that products including retatrutide, tirzepatide, semaglutide, survodutide, mazdutide, bremelanotide (PT-141) and tesamorelin were unapproved new drugs, despite their research-use labels. As evidence that the products were meant for people, the agency cited health claims on the websites, water sold alongside the vials for preparing injections and, in one case, an online "peptide calculator". The FDA says it has warned companies whose products were falsely labelled for research or "not for human consumption" and were sold directly to consumers with dosing instructions.1,
The consequences can be criminal. In July 2026 a US federal judge sentenced the owner of an online peptide business that used a research-use disclaimer to 70 months in prison after he pleaded guilty to selling unapproved drugs. In his plea he admitted knowing that the products were being marketed and sold for human consumption.19
Canada. Health Canada's April 9, 2026 advisory says peptides are generally regulated as prescription drugs in Canada and that unauthorised drug products are illegal. The seized products it lists as examples include BPC-157, TB-500 and retatrutide. It states that research-use labelling "does not make these products legal or exempt from regulatory requirements".6
Australia. The Therapeutic Goods Administration (TGA) said in April 2026 that peptide products are regulated as therapeutic goods and named BPC-157, TB-500 and retatrutide among unapproved examples. It stated that a "research use only" disclaimer does not make supply lawful and does not by itself change a product's regulatory status, permit importation or remove advertising and supply obligations. After a seizure in August 2026 it added that it is unlawful to import, advertise, manufacture and supply unapproved peptide products in Australia. The exceptions are narrow, such as a product compounded for a particular person, or a personal import that meets every condition of the Personal Importation Scheme.7,
United Kingdom. The Medicines and Healthcare products Regulatory Agency (MHRA) told The Pharmacist in April 2026 that it disregards "research purposes" claims when they are used to avoid medicines regulation, and acts when promotional material shows products are unauthorised medicines intended for human use. It decides case by case, and said that many peptides sold for bodybuilding without medicinal claims would not be considered medicines. Its criminal enforcement unit has raided sites making unlicensed retatrutide and tirzepatide pens, including a May 2026 raid it called its largest ever seizure of unlicensed weight-loss medicines.18,
What is known about quality
Regulators describe the same set of risks. Health Canada warns that unauthorised drugs may contain too much, too little or none of the active ingredient, unlisted ingredients, or contaminants such as solvents, heavy metals, particles and microbes, and may be poorly labelled or stored. The FDA says illegally sold semaglutide and tirzepatide may be counterfeit or contain the wrong ingredients. The TGA says it has no oversight of these products' composition or manufacturing standards, and that whether injectable products are sterile is unknown.6,
Independent laboratory testing is scarce, and the published studies are small. In a 2024 study, researchers in Hungary and the US ordered semaglutide from illegal online pharmacies selling without a prescription. Three vials arrived (the pens they ordered never did). The vials held about 29% to 39% more semaglutide than labelled, bacterial toxins (endotoxin) were found in all three, and measured purity was 7.7% to 14.4%, against the 99% claimed on the labels.15
A 2026 analysis of three products sold as retatrutide in Australia, submitted anonymously to a private drug analysis service, found that all three contained retatrutide, but the amount ranged from about half to almost double what the label stated (51%, 165% and 190% of the labelled content). Metal impurities were at trace levels, well below safety thresholds. Sterility and endotoxin were not tested.16
Both studies tested only three samples, so they cannot show how common these problems are across the market. They do show that the label and the seller's purity claim can be wrong. A certificate of analysis is only as reliable as whoever issued it: the owner in the US criminal case admitted forging laboratory certificates for his products.15,
For some research peptides, the substance itself raises questions. The FDA says BPC-157 may carry a risk of unwanted immune reactions (immunogenicity) and impurity problems, and that it lacks enough information to know whether it would cause harm in humans; for TB-500 it has found no human exposure data. The TGA has received reports concerning unapproved peptide products that include severe allergic reactions requiring adrenaline and hospital care, and severe inflammation throughout the body (systemic inflammatory response syndrome) needing hospital treatment.5,
How to check a peptide's regulatory status
- United States: Drugs@FDA lists FDA-approved prescription brand-name and generic drugs, over-the-counter drugs and many therapeutic biological products.
- European Union: medicines evaluated by the European Medicines Agency are on its website, and medicines authorised by individual countries are in each country's national register, which EMA links to.
- United Kingdom: the MHRA products website carries patient leaflets, product descriptions and scientific reports about marketing authorisations.
- Canada: authorised drugs carry an eight-digit Drug Identification Number (DIN) on the label and can be looked up in Health Canada's Drug Product Database.
- Australia: approved products are included in the Australian Register of Therapeutic Goods (ARTG); peptide products not included in it are unapproved.12,
13, 14, 6, 7
A vial that carries the name of an approved ingredient is not the approved medicine. The FDA says unapproved versions of drugs such as semaglutide and tirzepatide do not go through its review for safety, effectiveness and quality, and that retatrutide is not a component of any FDA-approved drug and has not been found safe and effective for any condition.3
Each PeptoKing peptide entry shows its regulatory status with sources. BPC-157 and TB-500 are listed as unapproved: Canadian and Australian regulators name both among unauthorised or unapproved peptide products. Retatrutide is listed as investigational: the MHRA describes it as a medicine in clinical development that has not been approved for UK use, and the FDA says it is not part of any approved drug. Status can change, so check the date on the entry and on the regulator's page.6,